Early Communication about an Ongoing Safety Review of Reductil (sibutramine hydrochloride)
2009-12-14
The Saudi Food and Drug Authority (SFDA), resembled by the National Pharmacovigilance Centre (NPC), is reviewing preliminary data from a recent study suggesting that patients using sibutramine have a higher number of cardiovascular events (heart attack, stroke, resuscitated cardiac arrest, or death) than patients using a placebo (sugar pill). Sibutramine is marketed as Reductil, a prescription drug, in Saudi Arabia.